Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002190 |
To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Saquinavir Drug: Lamivudine Drug: Zidovudine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Safety Study |
Official Title: | A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Prior Medication:
Excluded:
United States, California | |
Davies Med Ctr / c/o HIV Institute | |
San Francisco, California, United States, 94114 | |
Pacific Oaks Med Group / Rsch & Scientific Investigation | |
Sherman Oaks, California, United States, 91403 | |
United States, New York | |
Columbia Presbyterian Med Ctr | |
New York, New York, United States, 10032 |
Study ID Numbers: | 229N, NV15114 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002190 |
Health Authority: | United States: Food and Drug Administration |
Drug Therapy, Combination Zidovudine HIV Protease Inhibitors Lamivudine |
Saquinavir Reverse Transcriptase Inhibitors Anti-HIV Agents |
Virus Diseases Sexually Transmitted Diseases, Viral Saquinavir HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Lamivudine Zidovudine Retroviridae Infections Immunologic Deficiency Syndromes |
Antimetabolites Anti-Infective Agents HIV Protease Inhibitors RNA Virus Infections Anti-HIV Agents Slow Virus Diseases Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Protease Inhibitors Reverse Transcriptase Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections Nucleic Acid Synthesis Inhibitors |